NCT07241741Completed
The Predictive Role of Preoperative Pentraxin-3 (PTX3) in Metabolic and Inflammatory Outcomes After Roux-en-Y Gastric Bypass
A Single-Center Prospective Study on PTX3 as a Predictor of Insulin Resistance and Inflammatory Resolution After Bariatric Surgery
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 23 (actual)
- First submitted
- 3 Sept 2025
- Start date
- 1 Jan 2015
- Primary completion date
- 1 Jul 2015
- Lead sponsor
- Istanbul University
- Diseases
- Obesity
- NCT number
- NCT07241741
What you commit to
- Study type: Observational
- Participants enrolled: 23
- From 1 Jan 2015 to the primary completion date, 1 Jul 2015
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous bariatric surgery
Other illness
- Severe hepatic, renal, or cardiac failure
- Active infection or inflammatory disease
- Malignancy
Who the study is looking for
- Age: 18-65 years
- Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity
- Eligible for primary Roux-en-Y gastric bypass
- Able to provide written informed consent
Age in the registry: 18 days to 65 days · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.